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Abstract: The industrial production of chondroitin sulfate (CS) uses animal tissue sources as raw
material derived from different terrestrial or marine species of animals. CS possesses a heterogeneous
structure and physical-chemical profile in different species and tissues, responsible for the various
and more specialized functions of these macromolecules. Moreover, mixes of different animal tissues
and sources are possible, producing a CS final product having varied characteristics and not well
identified profile, influencing oral absorption and activity. Finally, different extraction and purification
processes may introduce further modifications of the CS structural characteristics and properties
and may lead to extracts having a variable grade of purity, limited biological effects, presence of
contaminants causing problems of safety and reproducibility along with not surely identified origin.
These aspects pose a serious problem for the final consumers of the pharmaceutical or nutraceutical
products mainly related to the traceability of CS and to the declaration of the real origin of the active
ingredient and its content. In this review, specific, sensitive and validated analytical quality controls
such as electrophoresis, eHPLC (enzymatic HPLC) and HPSEC (high-performance size-exclusion
chromatography) able to assure CS quality and origin are illustrated and discussed.
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1. Chondroitin Sulfate Structure
Hyaluronic acid (HA), keratan sulfate (KS), chondroitin sulfate (CS)/dermatan sulfate (DS) and
heparan sulfate (HS)/heparin are natural macromolecules and the main complex heteropolysaccharides
belonging to the class of glycosaminoglycans (GAGs) [1,2]. Apart from KS, which is composed of
galactose and N-acetyl-d-galactosamine (GalNAc) [3], the backbone of the other GAGs is commonly
represented by typical disaccharide sequences constituted of alternating units of uronic acids, glucuronic
(GlcA) or iduronic (IdoA), and amino sugars, N-acetyl-d-glucosamine (GlcNAc) or GalNAc [4]. KS,
CS/DS and HS/heparin are sulfated macromolecules possessing different degrees of charge density
thanks to the presence of sulfate groups in varying amounts and located in different positions. Moreover,
besides the variability in sulfate groups, these polysaccharides are very heterogeneous in terms of
molecular mass, physicochemical properties, and biological and pharmacological properties [1–4].
CS with different disaccharides and overall carbohydrate backbones may be biosynthesized
possessing various number and position of sulfate groups [4] (Figure 1). Consequently, CS is a largely
heterogeneous GAG formed of alternate and variously sulfated disaccharides of GlcA and GalNAc
linked by β(1→3) bonds. Moreover, the different disaccharides are linked to each other by β(1→4)
bonds. CSA and CSC are constituted by disaccharides sulfated in position C4 or C6 of the GalNAc
residue, respectively, and minor percentages of the monosulfated disaccharide on C2 of GlcA are
possible. Besides the main presence of these two kinds of disaccharide units monosulfated in position
C4 or C6 of GalNAc, disaccharides with a different number and position of sulfate groups can be
present, in various percentages, within the carbohydrate chains [4–6]. Various kinds of disulfated
disaccharides may be present in the CS structure in various amounts also in relation to specific animal
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sources (as in cartilaginous or bony fishes, see below), such as the disaccharide disulfated in position
C2 of GlcA and C6 of GalNAc (the so-called disaccharide D), in position C4 and C6 of the GalNAc unit
(the disaccharide E) or C2 of GlcA and C4 of GalNAc (the disaccharide B) (Figure 1). Finally, a low
percentage of the non-sulfated disaccharide is almost always present in the CS backbone while the
fully tri-sulfated disaccharide is generally in trace amount [4–6].
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IdoUA [4]. However, the biosynthetic processes generally produce highly modified oligosaccharide 
domains separated by regions having a low-degree of structural modifications introducing further 
heterogeneity. Consequently, the CS and DS chains may be hybrid polymers of low modified (CS) 
and highly modified (DS) domains [4]. The sulfation heterogeneity introduces a great variability in 
the position of sulfate groups and in CS charge density. Moreover, the different number of 
disaccharide units forming the CS polymer and the overall molecular weight generated are other key 
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level of sulfation [12]. In addition to its conventional structural roles in the composition of 
extracellular matrix and formation of organs and tissues, such as cartilages and bones, recent 
evidence demonstrates that CS chains are involved in important biological functions in inflammation, 
infection and wound repair [7–11]. 
Figure 1. Structure of the disaccharides present in chondroitin sulfate backbone constituted of
d-gluc onic acid and N-acetyl-d-galactosamine linked by β(1→3) bonds. The various disaccharides
are linked each other by β(1→4) link ges. Minor percentages of very rare dis ccharides m y also have
a sulfate group in position C3 of the glucuronic acid. Ac, acetyl group.
Besides the above-illustrated CS structures, a peculiar CS polysaccharide known as CSB or DS is
known in nature, formed of disaccharide units of IdoA and GalNAc mainly sulfated in position C4
with a minor and variable content of the disulfated disaccharide in position C4 of GalNAc and C2 of
IdoUA [4]. However, the biosynthetic processes generally produce highly modified oligosaccharide
domains separated by regions having a low-degree of structural modifications introducing further
heterogeneity. Consequently, the CS and DS chains may be hybrid polymers of low modified (CS) and
highly modified (DS) domains [4]. The sulfation heterogeneity introduces a great variability in the
position of sulfate groups and in CS charge density. Moreover, the different number of disaccharide units
forming the CS polymer and the overall molecular weight generated are other key factors influencing
its properties. Finally, the combination of the different sulfated disaccharides and oligosaccharide
domains produces a huge number of heterogeneous CS polymers possessing various, specific and
specialized biologic l an pharm cological fun ti ns [1,2].
2. Chondroitin Sulfate Activity
CS is a natural biomacromolecule abun l i tributed in virtually all invertebrates and
vertebrates (and consequently in humans) and involved in many biological proces es [1,5,7,8]. on
its rganism-to-organism and tissue- o-tissue str ctural diversity in cha length a d sulfation patterns,
CS rovides specific biological functions at molecular, cellular and organ level such as cell adhesion,
cell division and differentiation, morphogenesis, organogenesis and neural network formation [9–11].
Moreover, CS is particularly abundant in all mammalian connective tissues, especially in the cartilage,
skin, blood vessels, ligaments and tendons with different structure and level of sulfation [12]. In addition
to its conventional structural roles in the composition of extracellular matrix and formation of organs
and tissues, such as cartilages and bones, recent evidence demonstrates that CS chains are involved in
important biological functions in inflammation, infection and wound repair [7–11].
The biological effects of CS are related to its ability to interact with a wide variety of other
bio(macro)molecules including (but not limited to) matrix molecules, growth factors, protease inhibitors,
cytokines, chemokines, adhesion molecules and pathogen virulence factors via aspecific/specific sulfated
saccharide domains within the chains [11–13]. In fact, along with aspecific interactions due to its
numerous negative charges provided by the sulfate and carboxyl groups, CS is involved in specific
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binding to bioactive molecules for the presence of peculiar functional domain structures which are
formed by combinations of the various disaccharide units [11–13] (see Figure 1).
Osteoarthritis (OA) is a global issue affecting all known countries and ethnicities with huge
incidence and economic impact [14]. OA particularly affects the older population producing variable
degrees of limitation of movement and major activities of daily living. Moreover, OA is expected to
dramatically rise in the future, in particular for the population above 70 years of age [14–16], also
related to the observed increase of obesity in western populations [17,18]. Current treatments are
mainly based on pain reduction [19] and treatments having the aim to reduce the progression of
the disease, such as the S/DMOADs (structure/disease modifying anti-osteoarthritis drugs) [20,21].
CS inhibits the extracellular proteases involved in the metabolism of connective tissues, and it is
able to stimulate proteoglycans production by chondrocytes as well as reduce the cartilage cytokine
production but also to induce apoptosis of articular chondrocytes [8,22]. Furthermore, CS increases the
intrinsic viscosity of the synovial liquid and, in bones, it accelerates the mineralization process and
repair [8,22]. Overall, CS has a key role in articular and bone metabolism by controlling cartilaginous
matrix integrity and bone mineralization. Consequently, with others, treatment with CS is reported
to improve OA symptoms and to reduce the disease. In fact, in many published studies, CS has
demonstrated to be a symptomatic slow acting drug for the treatment of OA (SYSADOA) and to have
disease modifying properties in long-term treatments (so-called DMOAD) (see [20–24] for reviews).
3. Safety and Quality Concerns of Chondroitin Sulfate
CS, according to its nature, must be extracted from animal sources and submitted to purification
processes for commercial purposes [5,6]. Actual commercial production of CS is based on terrestrial
raw material, from bovine, porcine, and chicken, or marine sources such as cartilaginous fish, sharks
and skate, but also bony fishes ([5,6,25] and personal information). Moreover, a mix of all these
sources is possible, producing a CS final product with mixed characteristics and properties. The use of
possible not controlled raw animal material (tissues, bones and cartilages but also soft organs) poses
the problem of a final product with not controlled structure and poor reproducibility along with the
not well identified origin with the consequence of variable grade of purity, biological effects, presence
of contaminants, clinical efficacy and safety [5,6,26].
Besides the source material, manufacturing processes, the presence of contaminants and other
natural biomolecules, as well as many other factors, contribute to the quality, structure and properties of
the final product influencing CS overall biological, nutraceutical and pharmacological capacities. In fact,
as well known, CS possesses a complex structure strictly depending on the tissue, organ and species
but also on the age of the animals [5,6]. Moreover, the biological and nutraceutical properties may vary
with the structure as well as the oral absorption that is influenced by the different CS physicochemical
properties [27–29]. Furthermore, due to the extractive origin of CS and to the different purification
processes applied, the presence of bacteria, virus or prions cannot be excluded [30]. Additionally,
other various natural bioactive (macro)molecules may be present in different content as contaminants
in CS final extracts [5,6], and voluntary adulteration by artificial compounds is also known. Finally,
a restriction use related to religious issues is possible (see below for these CS concerns). Overall,
depending on the source origin and on the manufacturing processes, variable CS final products for
structure, quality and activity may be produced (Table 1) [5,6,26].
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Table 1. Main general characteristics and properties of animal CS for commercial purposes.
Variable and generally not defined and heterogeneous source of extraction
Possible cross-contamination between sources of different origin
Possible presence of bacteria, virus and/or prions
High content of proteins that are not characterized (up to 5–10%). Some of these proteins may have
allergenic potential able to develop immune reactions
Variable content of immunogenic keratan sulfate and other natural biopolymers
Variable purity
Heterogeneous structure and physicochemical properties. Variable molecular mass, polydispersity and
charge density
Process of extraction generally not controlled causing possible modifications of the CS structure, such as
desulfation and/or depolymerization
Possible intentional adulteration by artificial (macro)molecules
Possible batch-to-batch variability
In general, no evaluation of any biological activity
CS from various sources has a carbohydrate backbone formed of disaccharides with sulfate groups
in different percentages and positions (see Figure 1) producing polymers possessing different charge
densities. Furthermore, due to the biosynthetic processes, CS macromolecules with different grades of
polymerization may be generated with various molecular masses and polydispersity related to specific
tissues, organs and species. Because of these structural variations, and the further possible presence of
specific oligosaccharide sequences (and purity, see below) of the preparations for therapy applications
or in nutraceuticals, CS may have different biological properties and capacities [5,26]. According to
this structural variability, different and peculiar activities have been reported depending on the CS
structure [5]. Finally, bioavailability and pharmacokinetic have been reported to change depending on
CS structural properties and origin when orally administered during therapy [27–29].
Extraction and purification processes may further produce CS preparations having different
structures introducing modifications of the macromolecular characteristics and chemical properties by
controlled as well as undesired depolymerization, desulfation and/or chemical modifications [6].
Another key point is related to the accurate evaluation of the CS content and purity when the
preparation is produced for therapeutic or nutraceutical applications. In fact, the CS content and
purity may change according to the manufacturing processes and/or tissue sources. Depending on the
purification protocols, the extracts may have a variable content and purity of CS due to the presence of
polluting inorganic or organic side-products (Table 1).
All the above-mentioned aspects pose a serious problem for the pharmaceutical or nutraceutical
Companies having the necessity to declare the real origin of the active ingredients and the label
traceability of CS from the raw material up to the finished products. Moreover, an accurate label
indication of the CS content is of paramount importance to assure to the final consumer a real
dose administration also considering the possible intentional adulteration by potentially dangerous
(macro)molecules (see below) mimicking CS structure and properties.
3.1. Natural Contaminations
As already mentioned, commercial CS produced from animal sources requires long and complex
procedures of extraction and purification with the aim to eliminate or reduce the content of the other
(macro)molecules present as natural contaminants [26] (Figure 2). At the same time, contamination of
CS may be accidentally caused by the same extraction and purification processes if not well controlled.
Obviously, as more steps of purification are adopted having differential capacities in the elimination of
natural contaminants of various nature, CS final products with higher quality may be obtained. On the
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other hand, the production of high-quality CS of pharmaceutical grade generally requires high costs of
production and quality analytical controls.Molecules 2019, 24, x FOR PEER REVIEW 5 of 13 
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Figure 2. Natural contaminations eventually present in chondroitin sulfate preparations and responsible
for reduced title and possible side-effects.
3.1.1. Polysaccharides
Depending on the animal source and on the extraction and purification procedures that generally
are complex and require long time, CS extracts and final products for commercial purposes are also
polluted with variable percentages of other polysaccharides that are co-extracted with CS during its
preparation (Figure 3).
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Figure 3. Natural polysaccharides eventually present in chondroitin sulfate preparations and the
consequences on the chondroitin quality and title.
HA in particular, and DS with its carbohydrate backbone made of iduronic acid, have been
detected in raw materials and formulations and reported in scientific papers [31] due to their ubiquitous
presence in tissues from which CS is generally produced. Moreover, KS has been detected in many
batches of CS produced from shark cartilage, averaging 16% of the total GAGs [32,3 ] ( 4).
Indeed, as KS i involved in the struc ure of the prote glycan ggrecan located in all cartilages, it has
been det cte in extracts and finished preparations of vari us origin along with CS extracted from the
same car ilages [34]. A total of 15 samples, including four samples of CS as lab ratory reagen s, one
sample of CS as a food additive nd ten samples of dietary supplem nts containing CS, were examined
for the presence of KS by using sp cific immunodiffusion and enzyme-linked immu osorbe t assay
(ELISA). Apart from the three samples of CS as laboratory reagents, all samples were found to contain
varying amounts of KS [34]. Finally, it is worth mentioning that KS possesses im unogenic capacities
able to develop immune reactions [35]. Depending on the animal raw material used for CS extraction,
HS may also be present due to its comparable physicochemical properties with CS, in particular for its
nature of sulfated heteropolysaccharide [12].
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Figure 4. Acetate cellulose electrophoresis able to detect the presence of (A) keratan sulfate (KS) or
(B) dermatan sulfate (DS) and/or heparan sulfate (HS) in chondroitin sulfate (CS) preparations (material
owned by the same au or).
The presence of thes natural polymers in t , also in high percentages, alerts the
manufacturers for improved isolation procedures as well as the supervisory agenci s for better audits.
In addition, this finding also compr mises the d ired amounts f the real ingredient specifi d on the
label claims and forew rns the pharmaco ei s to update their monographs. In fact, general non-specific
analytical methods such as CPC (cetylpyridinium chloride) titration and carbazole assay are unable
to detect the presence of other polysaccharides in CS products due to their quite similar properties
and chemical structures (see below for further analytical considerations). Finally, the presence of
variable amounts of the immunogenic KS poses serious problems related to the possible development
of immunogenic adverse reactions (Figure 3).
3.1.2. Other Biomolecules
Other (macro)molecules possessing similar properties of CS are copurified during CS extraction
from tissues, such as nucleic acids [31] and proteins (Figure 5). In fact, animal tissues and organs
are rich in DNA, RNA and proteins, and variable content of these biomolecules are present in CS
extracts depending on the source and on the purification protocols adopted. Moreover, some of these
proteins may have allergenic and/or intolerance capacity able to develop immune reactions. Finally,
these macromolecules also give positive response to aspecific analytical controls such as CPC assay [6]
(Figure 5).
Molecules 2019, 24, x FOR PEER REVIEW 6 of 13 
 
  
Figur  4. Acet te cellulose electr phore is able to dete t the presence of (A) keratan sulfate (KS) or 
(B) dermatan sulfate (DS) and/or heparan sulfate (HS) in chondroitin sulfate (CS) preparations 
(material owned by the same author). 
The p sence of th se natural olymers in CS products, also in high percentages, alerts the 
manufacturers f r improved isolation ce ures as well as the supervisory agencies for bett r 
audits. In addition, this finding also compromises the desired amounts of the real ingredient specified 
on the label claims and forewarns t e pharmacopeias to update their monographs. In fact, gener l 
non-specific analytical methods such as CPC (cetylpyridinium chloride) titration and carbazole assay 
are unable to etect the presence of oth r polysaccharides in CS products due to their quite similar 
rop rti s and chemical structures (see below for furth r analytical considerations). Finally, th  
pres nce of variable am unts of th  immunogenic KS poses serious problems related to the possible 
development of immunogenic adverse reactions (Figure 3). 
3.1.2. Other Biomolecules 
Other (macro)mole ules pos essing similar properties of CS are copurified during CS extraction 
from tissues, such as nucleic acids [31] and proteins (Figur  5). In fact, anim l tissues and organs are 
rich i  DNA, RNA and proteins, and variable content of these biomolecules a e present in CS extracts 
depending on the source and on th  purifi tion protocols adopted. Moreover, some of these proteins 
y have allergenic and/or intolerance capacity able to develop immune reaction . Finally, these 
macrom lecules also give positive response to aspecific analytical controls such as CP  assay [6] 
(Figure 5). 
 
Figur  5. Natural biomolecules possibly present in chondroitin sulfate preparations and their related 
problems. 
Figure 5. biomolecules possibly present in chondroitin sulfate prep rations and their
related problems.
Molecules 2019, 24, 1447 7 of 13
3.1.3. Infective Agents
The animal origin of CS may pose safety problems due to the possible presence of pathogen
contamination and transmissible infective agents such as bacteria residues, viruses and prions
potentially causing spongiform encephalopathy in bovines (BSE), foot-and-mouth disease, influenza
spread in birds and other animal diseases (Figure 5). The possible presence of infective agents in
the organs and tissues used for CS production requires the application of specific chemical steps
able to destroy or inactivate and eliminate bacteria, viruses and prions [36,37] possibly introducing
chemical modifications in the CS structure such as degradation, desulfation, oxidation of carbohydrate
chains, introduction of chemical groups, etc. In fact, prions adhere very tenaciously to surfaces,
making them hard to remove, and their resistance to protease treatment, certain chemical agents and
heat denaturation represents a major concern for pharmaceutical products derived from terrestrial
animals [36]. Moreover, the purification steps useful to remove the infective agents can also affect the
biological capacities of extracted CS (Figure 6).
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Figure 6. Com on possible pathogen conta i ti transmi sible infective agents in chondroitin
sulfate preparations and their effects.
Another key point is the adoption of spe ifi l ctive analytical assays to d tect the possible
presence of the differ nt infective a i the final products. In fact, th presence of prions may
be strated with a diagnostic test. However, the current available nalytic l ssays are
characterized by high costs and limited to s ecialize la ratories [38]. Finally, other pathogens show
similar attributes as prions for the potential risk of carry-over into final purified products.
3.2. Inte tional Adulterations
Besides the presence of natural contamination, finished CS preparations may also be adulterated
by the voluntary addition of cheaper polysaccharides and organic derivatives unable to be determined
with usual analytical controls utilized in the nutraceutical industry (Figure 7). In fact, CS is well
known to be one of the most adulterated supplements in the market, a widespread and probably
underestimated problem, abetted by the lack of industry-wide specific and sensitive quality control
analytical methods with several of the adulterated agents going undetected [6,39].
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Approximately 80–90% of the CS supplied to the US and Europe markets is produced in China
and intentional adulteration is possibly practiced by nutraceutical manufacturers globally with the aim
to reduce ingredient costs by using cheaper substances [40]. The price pressure is also responsible for
poor purification procedures with the production of CS preparations rich in salts and having low title
but also to minimize analytical controls to only c mmon non-specific and inexpensive tests [40]. In this
scenario, some aw mate ial and d et ry supplement products contain less than the claimed a ount
of CS, in some cases as little a 5–10% [41,42] with a huge fraud to clients, trad rs and consumers
(Figure 7). In fact, many studies available in scientific literature demonstrate the poor quality and a
title not conforming to label declaration of many CS finished products in several countries [6,41–45].
The application of specific analytical methods such as eHPLC (enzymatic HPLC), HPSEC
(high-performance size-exclusion chromatography) and electrophoresis (Figure 4 and see below for
analytical methods) on commercially available nutraceuticals has demonstrated the poor quality of
many of these products in the global market showing a lower concentration of CS than specified
on the label as well as their intentionally adulteration [39,41,42]. The adulteration is obtained with
molecules that may interfere with aspecific widely-used analytical methods of CS quantitation, such as
the CPC titration and carbazole assay, to give an artificially inflated estimate of CS concentration [6].
Many (macro)molecules have been identified for CS adulteration, such as carrageenan, proteins and
surfactants, cheaper polysaccharides, sodium alginate, propylene glycol alginate sulfate sodium,
sodium hexametaphosphate com l n with the name of Calgo and used as a detergent
or ent ditive [39], maltodextrin and lactose [42] (Figure 7). Th se substances can be
separated from real CS by their difference in electrophoretic mobil ty (Figure 4) and a cor ect title of CS
may be obtained by other specific analytical approaches such as eHPLC and HPSEC (see below), and
not with commonly-used methods [6,39,41,42] (Figure 7).
4. Analytical Quality Controls
CS for pharmaceutical applications is strictly evaluated for quality, content, structural
characterization and parameters (such as charge density and olecular mass) by means of sensitive,
specific, validated and published analytical approaches [6]. These features are of paramount importance
to ensure therapeutic reproducibility and safe use, and to protect patients from ineffective and/or
unsafe and potentially dangerous drugs. As discussed below, is it possible to affirm the same for food
and nutraceutical CS preparations?
European and USA pharmacopoeias require some analytical tests for CS identification such
as infrared spectroscopy, specific optical rotation, intrinsic viscosity, electrophoresis and CPC
titration [46,47]. Some of these assays are very old and usually no longer used in modern quality control
laboratories due to their lack of specificity, low sensitivity and poor reproducibility. In particular,
infrared spectroscopy and specific optical rotation cannot give specific information belonging to
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many other (macro)molecules, such as the absorption of chemical groups in the spectrum of infrared
wavelengths (for infrared spectroscopy) [48] or the capacity to rotate the plane of polarization of
plane-polarized light by chiral chemical compounds such as carbohydrates (for optical rotation) [49].
Intrinsic viscosity measurement is a very old technique for the determination of the molecular weight
of a polymer replaced by the more modern size-exclusion chromatography coupled with various
detectors [50] (Figure 8). The industry-wide method for analysis of CS is CPC titration. However,
several flaws in this old testing method show relevant limits, as it can be tricked by the use of natural
macromolecules and/or artificial adulterants and cannot distinguish between CS and other material
having similar physicochemical properties, e.g., nucleic acids, anionic proteins, other polysaccharides,
etc. [6]. Moreover, CPC assay is also influenced by the molecular weight of tested CS as well as for
the carbazole assay that is another non-specific quantitative test [6]. On the contrary, agarose-gel
electrophoresis according to European pharmacopoeia, electrophoresis on acetate of cellulose (ACE)
according to US pharmacopoeia, and HPSEC and eHPLC according to the AOAC (Association of
Official Analytical Chemists) [51] are highly specific analytical approaches for the determination of CS
quality, quantity, chemical properties and structure.
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Besides the low title, als i i of CS has the been reported to be a puzzle and in general
not declared on product abels [6]. The rigin of he CS util zed in a finished product can only
be detected by rather expensive and detailed biochemical/structur analyses by determining the
disaccharide/oligosaccharide pattern an l l r a s parameters [6]. According to this, a
combination of specific analytical methods to define the final quality, origin and properties of the product
is required. Such methods include electrophoresis, HPSEC, selective enzymatic treatment and further
separation of the constituent disaccharides/oligosaccharides using sophisticated techniques including
capillary electrophoresis [31,52,53], HPLC [5,6,54,55], FACE (Fluorophore-Assisted Carbohydrate
Electrophoresis) [42,56] and mass spectrometry [57]. CS profile is achieved using well-established
multi-analytical laboratory techniques, particularly electrophoresis, HPSEC and eHPLC (Figure 8) [5,6]
due to their high throughput, sensitivity and reproducibility. These techniques, applied before and
after enzymatic digestion of CS into smaller components, can distinguish between CS derived from
different animal or marine sources based on disaccharide content, patterns of sulfation and molecular
size of the polymer (Figure 8) also using analytical standards of CS of different origin (see below).
However, a big problem remains for the sure identification of the origin of CS when mixed source
material is used to its producti or in the case of possible cross-contamination.
The use of animal-derived sources to produce commercial CS also represents a concern for
vegetarians and people with dietary restrictions related to religious and supply issues. In fact,
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religious reasons and/or the practice of abstaining from the use of animal products have precluded the
introduction of CS dietary supplements both in key emerging markets, such as Middle East and Asia,
and in consolidated markets.
The application of the above-illustrated multi-analytical techniques, electrophoresis, HPSEC and
eHPLC requires highly qualified laboratories equipped with dedicated instrumentation and qualified
technicians with specific analytical know-how producing very expensive activity and elevated costs
for high quality CS management (Figure 8). Moreover, an accurate and reproducible quantitative assay
requires reference standards with high specificity, purity and well-known physicochemical properties
and structures [6]. This is not a simple task in the case of CS due to its high heterogeneity of structure
and properties mainly depending on the source and purification protocols, as previously discussed.
However, several reference standards are commercially available, such as the CS standard from bovine
cartilage manufactured by Bioiberica (www.bioiberica.com/) and possessing a purity greater than
98% and approved in 2004 as Chemical Reference Substance (CRS) by the European Pharmacopeia
Commission [6]. Furthermore, other standards are available such as the European pharmacopoeia
reference standard of CS sodium of marine origin (https://www.sigmaaldrich.com/) or the CS sodium
salt from shark cartilage (https://www.sigmaaldrich.com/).
5. Conclusions
In 2008, heparin manufactured in China was intentionally adulterated with an oversulfated CS
polymer having a very high charge density quite similar to natural heparin, which provoked hundreds
of deaths in Europe and USA after intravenous administration [58]. As for heparin, an important
natural drug derived from animals, intentional adulteration of CS is difficult to detect since the tissue
supply chain for CS in slaughterhouses generally lacks current good manufacturing processes (cGMP)
oversight assuring high-quality CS production along with specific analytical quality controls. Moreover,
as mentioned above, CS is derived from a variety of animal tissues potentially containing infectious
agents leading to the transmission of viral, bacterial and prion diseases and the intentional or accidental
mixing of CS from different animal species is highly suspected. In fact, some countries do not have a
strict biosecurity system able to reduce the risk of the introduction and spread of disease agents.
Even if specific and high-level analytical methods are generally able to distinguish from various
sources, the detection of the presence of small amounts of different raw material remains very difficult.
Additionally, CS structure can vary with environmental factors, animal subspecies, age and/or tissues
providing additional difficulties for its quality and properties standardization. Moreover, the missing
guidelines allow manufacturers of finished products to often change the sources of supply of the
animal tissues or CS raw materials for competitive advantages. Consequently, the urgent solution to
this scenario is the introduction and utilization in the current market of validated, specific, scientifically
sound and largely published analytical controls. Manufacturers should ensure traceability of raw
material right through to the finished product, with analytical evaluation made of each lot supplied to
guarantee same quality, reproducibility and safety, as well as avoid misleading label information on
finished products as reported in the literature.
In conclusion, specific and accurate analytical procedures should be enforced for the control of
high-quality products and applied by quality control laboratories to confirm the purity and label claims
of CS in raw materials and finished products for food and nutraceutical applications. Finally, there
are no definite regulations and common acceptance governing the origin of the ingredients in these
supplements and the origin of the ingredients in products of natural and extractive origin is one of the
most important factors ensuring quality, safety and efficacy.
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